Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

por Tan, H, Gupta, P, Harness, J, Wolk, R, Chapel, S, Menter, A, Strober, B, Langley, RG, Krishnaswami, S, Papp, KA
Publicado 2013

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis o...

por Strober, B., Menter, A., Leonardi, C., Gordon, K., Lambert, J., Puig, L., Photowala, H., Longcore, M., Zhan, T., Foley, P.
Publicado 2020

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study

por Van Voorhees, A.S., Stein Gold, L., Lebwohl, M., Strober, B., Sofen, H., Papp, K., Bagel, J., Zhang, Z., Paris, M., Wang, Y.
Publicado 2021

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patien...

por Gooderham, M., Pinter, A., Ferris, L.K., Warren, R.B., Zhan, T., Zeng, J., Soliman, A.M., Kaufmann, C., Kaplan, B., Photowala, H., Strober, B.
Publicado 2022

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from...

por Mease, P.J., Palmer, J.B., Hur, P., Strober, B.E., Lebwohl, M., Karki, C., Reed, G.W., Etzel, C.J., Greenberg, J.D., Helliwell, P. S.
Publicado 2019

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

por Strober, B.E., Gottlieb, A.B., van de Kerkhof, P.C.M., Puig, L., Bachelez, H., Chouela, E., Imafuku, S., Thaçi, D., Tan, H., Valdez, H., Gupta, P., Kaur, M., Frajzyngier, V., Wolk, R.
Publicado 2018